Genentech Links With Arvinas On Protein Degradation
This article was originally published in Scrip
Genentech, a member of the Roche Group, provided an undisclosed upfront payment and may invest more than $300m in milestone fees to use PROTAC, Arvinas Inc.'s targeted protein degradation technology, to create novel drugs against multiple disease targets.
You may also be interested in...
Lilly, Allergan and Biohaven plan to launch oral drugs for on-demand treatment of migraine attacks in the first quarter, hoping to harness a large market where new preventive therapies are already competing for patients.
Private Company Edition: VC deals fell short of the record-breaking level seen in 2018 and financings may slow a bit more in 2020. Also, UPMC and Frazier close new VC funds, and Emendo raises $61m for gene-editing platform.
Monia told Scrip at the J.P. Morgan Healthcare Conference that the company will be more selective about partnerships going forward and build commercial capabilities to market Ionis-owned drugs.